TRU NIAGEN® Earns NSF International’s Certified for Sport® Certification
24 September 2018 - 8:30PM
ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based,
nutraceutical company devoted to improving the way people age with
its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®,
today announced its TRU NIAGEN product recently earned
certification from NSF International’s Certified for Sport® program
and is available for purchase.
The sole active ingredient in TRU NIAGEN is nicotinamide
riboside, a unique form of vitamin B3 clinically proven to safely
increase one’s levels of NAD (nicotinamide adenine dinucleotide)
and enhance muscle recovery. Decreased NAD levels have been
associated with many age-related changes in overall health.
“It is exciting news that TRU NIAGEN, directly from ChromaDex,
is now an option for professional sports teams, especially those
that have already been benefiting from Niagen,” says, Dr. Rudolph
Tanzi, Professor of Neurology at Harvard Medical School,
Co-Director of the McCance Center for Brain Health at Massachusetts
General Hospital and world-renowned Alzheimer’s researcher.
Products earning Certified for Sport® certification are tested
for over 272 athletic banned substances as well as potentially
harmful levels of specific contaminants like lead and arsenic.
Product formulation, label claims and Good Manufacturing Practice
(GMP) compliance are also verified as part of this rigorous
supplement certification program.
NSF International’s Certified for Sport® program helps athletes
and consumers make more knowledgeable decisions when choosing
supplements. MLB, NHL and CFL clubs provide and recommend products
that are Certified for Sport® and players are urged to use only
these certified products. The Certified for Sport® certification is
also recommended by the NFL, PGA, LPGA, CCES, CPSDA and Taylor
Hooton Foundation as well as many other sports organizations.
“We are delighted to make TRU NIAGEN available to professional
athletes,” says Robert Fried, ChromaDex CEO. “NIAGEN, our
proprietary ingredient, has been successfully reviewed twice under
the FDA’s new dietary ingredient (NDI) program and we are pleased
to offer consumers this additional safety certification.”
“Athletes and consumers can choose Certified for Sport® products
with confidence. TRU NIAGEN is now certified by one of the most
rigorous certification programs in the dietary supplement
industry,” said Cheryl Luther, General Manager of Dietary
Supplements, Sports Nutrition and Beverage Quality at NSF
International.
For additional information on the science supporting TRU NIAGEN
visit www.truniagen.com.
About TRU NIAGEN®:TRU NIAGEN® is a branded
dietary supplement brought to market by key nicotinamide riboside
innovator and patent holder, ChromaDex. NIAGEN® nicotinamide
riboside (NR), also supplied by ChromaDex, is the sole active
ingredient in TRU NIAGEN®. Multiple clinical trials demonstrate
NIAGEN® is proven to boost NAD (nicotinamide adenine dinucleotide)
levels, which decline with age. Only NIAGEN® has twice been
successfully reviewed under FDA's new dietary ingredient (“NDI”)
notification program, and has also been successfully notified to
the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:
ChromaDex Corp. is an integrated, global
nutraceutical company devoted to improving the way people age.
ChromaDex scientists partner with leading universities and research
institutions worldwide to uncover the full potential of NAD and
identify and develop novel, science-based ingredients. Its flagship
ingredient, NIAGEN® nicotinamide riboside, sold directly to
consumers as TRU NIAGEN®, is backed with clinical and scientific
research, as well as extensive IP protection. TRU NIAGEN® is
helping the world AGE BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 30, 2017, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a portion of
the grant funding as a collaborator for the study.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships949-648-3775alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Sr. Director of FP&A and Investor Relations(949)
600-9727briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024